Highlights
- Life360: Goldman Sachs recommends Life360 as a buy, forecasting significant revenue growth driven by subscription momentum and a high-margin advertising stream.
- Lovisa Holdings: Morgans sees Lovisa as a standout in global retail, citing its strong sales and EBIT growth in challenging market conditions.
- Target Prices: Goldman Sachs sets a AU$25.00 price target for Life360, while Morgans places a AU$36.00 target on Lovisa.
Two ASX-listed companies, Life360 Inc and Lovisa Holdings Ltd, have recently been spotlighted by leading brokers for their robust growth potential and promising financial outlooks. Here's a closer look at why these stocks could be worth considering for your portfolio.
Life360 Inc (ASX:360)
Goldman Sachs has identified Life360, a leader in location technology, as a compelling growth opportunity for investors. The company is renowned for its Life360 app, which helps families stay connected and safe. With over 70 million monthly active users (MAU) across 150 countries, Life360 has already demonstrated its global appeal.
Despite its impressive reach, Goldman Sachs believes Life360 is still in the early stages of its growth journey.
Goldman Sachs has issued a buy rating on Life360's shares with a target price of AU$25.00. This optimism is based on the app's ability to expand its subscription base and monetize advertising, creating a long-term revenue growth trajectory.
Lovisa Holdings Ltd (ASX:LOV)
Another top pick among ASX growth stocks is Lovisa, a global fashion jewelry retailer known for its trendy and affordable designs. With 150 new styles introduced weekly, the brand has carved out a niche in the fast-paced world of fashion accessories.
Morgans has praised Lovisa for its exceptional financial performance, even amid challenging economic conditions. In FY24, the company achieved 17% sales growth and 21% EBIT growth, a rare feat in the current retail environment.
Morgans has issued an "add" rating for Lovisa with a price target of AU$36.00. The broker believes the company’s consistent growth and ability to navigate a tough market make it a strong candidate for long-term investment.